Patent details

Title (priority date) Treating cancer by modulating a MNK (12.11.2008)
Reference: 52995
Inventors: Grzmil, Hemmings, Merlo & Morin
Description: This patent application relies on the inventors' findings that found that a MNK is significantly elevated in human brain tumors and that the inhibition of said MNK in a cancer cell lines leads to a drastic increase of the sensitivity of these cells to the mTOR inhibitor rapamycin
Applications: Target, drug development, screening
Status: Pending EP & US
Opportunity: Exclusive and non exclusive license
Contact: Dr. Nicolas Favre, tel: +41 61 697 8382,
PCT File: WO 2010/055072
About this site2018 © FMI Basel Switzerland